Research programme: autologous chimeric antigen receptor T cell therapies - Poseida Therapeutics

Drug Profile

Research programme: autologous chimeric antigen receptor T cell therapies - Poseida Therapeutics

Alternative Names: Autologous CAR T-cell therapies - Poseida Therapeutics; Autologous CAR-based immuno-oncology therapeutics - Poseida; Autologous CAR-T therapies - Poseida Therapeutics; P PSMA 101

Latest Information Update: 23 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Poseida Therapeutics
  • Developer Janssen Biotech; Poseida Therapeutics
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Multiple myeloma; Solid tumours

Most Recent Events

  • 20 Jul 2018 Poseida Therapeutics announces intention to file an IND application with the US FDA in 2019
  • 20 Jul 2018 Poseida Therapeutics plans a clinical trial of P PSMA 101
  • 14 Feb 2018 Pharmacodynamics data from a preclinical trial in Solid tumours released by Poseida Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top